The modern view on neoadjuvant drug therapy for luminal/ non-luminal HER2-positive breast cancer
DOI: 10.32364/2618-8430-2024-7-4-3
L.V. Krivolapova1, A.Yu. Popov2, E.A. Andreenko3, E.V. Batukhtina1, V.O. Meshcherin1, N.A. Averina1, S.O. Popov1, A.A. Gritskevich2,3
1Academician B.V. Petrovskiy Russian Scientific Center of Surgery, Moscow, Russian Federation
2A.V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russian Federation
3RUDN University, Moscow, Russian Federation
Today, breast cancer (BC) is the most commonly diagnosed cancer in women. HER2-positive BC is one of the BC subtypes which is characterized by presence/absence of estrogen and progesterone receptors and, most of all, overexpression of the human epidermal growth factor receptor-2 (HER2) determining both the disease prognosis and treatment strategy. Unfortunately, actual therapy of early HER2-positive cancer considering all the "targets" does not fully achieve all the goals, the main of which are a pathological complete response and decreased incidence of cardiac complications after the treatment. This determines the relevance of searching for all the possible significant predictive factors of response to the drug therapy, reduced risk of cardiac complications and pharmacoeconomical justification of the therapy regimens. A presented literature review identifies the most important and relevant issues associated with neoadjuvant drug therapy of luminal/non-luminal HER2-positive BC along with possible solutions.
Keywords: neoadjuvant chemotherapy, targeted therapy, luminal HER2-positive subtype, non-luminal HER2-positive subtype, pathological complete response (pCR), anthracycline-free regimens.
For citation: Krivolapova L.V., Popov A.Yu., Andreenko E.A., Batukhtina E.V., Meshcherin V.O., Averina N.A., Popov S.O., Gritskevich A.A. The modern view on neoadjuvant drug therapy for luminal/non-luminal HER2-positive breast cancer. Russian Journal of Woman and Child Health. 2024;7(4):307–316 (in Russ.). DOI: 10.32364/2618-8430-2024-7-4-3
About the authors:
Lyubov' V. Krivolapova — Head of the Department of Antitumor Drug Therapy with a Day Hospital, Academician B.V. Petrovskiy Russian Scientific Center of Surgery; 2, building 1, Abrikosovskiy lane, Moscow, 119435, Russian Federation; ORCID iD 0009-0009-2544-068X
Anatolyi Yu. Popov — C. Sc. (Med.), Head of the Department of Chemotherapy, A.V. Vishnevsky National Medical Research Center of Surgery; 27, Bol'shaya Serpukhovskaya str., Moscow, 117997, Russian Federation; ORCID iD 0000-0001-6267-8237
Elena A. Andreenko — resident, RUDN University; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; ORCID iD 0009-0001-3507-8030
Elena V. Batukhtina — C. Sc. (Med.), Head of the Department of General Oncology and Reconstructive Plastic Surgery, Academician B.V. Petrovskiy Russian Scientific Center of Surgery; 2, building 1, Abrikosovskiy lane, Moscow, 119435, Russian Federation; ORCID iD 0000-0003-0187-6998
Vladislav O. Meshcherin — oncologist, Department of Antitumor Drug Therapy with a Day Hospital, Academician B.V. Petrovskiy Russian Scientific Center of Surgery; 2, building 1, Abrikosovskiy lane, Moscow, 119435, Russian Federation.
Nataliya A. Averina — oncologist, Department of Antitumor Drug Therapy with a Day Hospital, Academician B.V. Petrovskiy Russian Scientific Center of Surgery; 2, building 1, Abrikosovskiy lane, Moscow, 119435, Russian Federation.
Sergey O. Popov — C. Sc. (Med.), Chief Physician of the Scientific Clinical Center No. 1, Academician B.V. Petrovskiy Russian Scientific Center of Surgery; 2, building 1, Abrikosovskiy
lane, Moscow, 119435, Russian Federation; ORCID iD 0000-0002-4488-1597
Alexander A. Gritskevich — Dr. Sc. (Med.), Head of the Department of Urology, A.V. Vishnevsky National Medical Research Center of Surgery; 27, Bol'shaya Serpukhovskaya str., Moscow, 117997, Russian Federation; Professor of the Department of Urology and Operative Nephrology with Oncourology Course, Medical Institute, RUDN University; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; ORCID iD 0000-0002-5160-925X
Contact information: Lyubov' V. Krivolapova, e-mail: krivllv@yandex.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 01.10.2024.
Revised 24.10.2024.
Accepte 19.11.2024.2. Брагина О.Д., Деев С.М., Чернов В.И., Толмачев В.М. Эволюция таргетной радионуклидной диагностики HER2-позитивного рака молочной железы. Acta Naturae. 2022;14(2):4–15. DOI: 10.32607/actanaturae.11611Bragina O.D., Deyev S.M., Chernov V.I., Tolmachev V.M. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. Acta Naturae. 2022;14(2):4–15. DOI: 10.32607/actanaturae.11611
3. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. DOI: 10.3322/caac.21834
4. Wilkinson L., Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033. DOI: 10.1259/bjr.20211033
5. Schettini F., Pascual T., Conte B. et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020;84:101965. DOI: 10.1016/j.ctrv.2020.101965
6. Obeagu E.I., Obeagu G.U. Breast cancer: A review of risk factors and diagnosis. Medicine (Baltimore). 2024;103(3):e36905. DOI: 10.1097/MD.0000000000036905
7. Obeidat O., Charles K.R., Akhter N., Tong A. Social Risk Factors That Increase Cardiovascular and Breast Cancer Risk. Curr Cardiol Rep. 2023;25(10):1269–1280. DOI: 10.1007/s11886-023-01957-9
8. Scala M., Bosetti C., Bagnardi V. et al. Dose-response Relationships Between Cigarette Smoking and Breast Cancer Risk: A Systematic Review and Meta-analysis. J Epidemiol. 2023;33(12):640–648. DOI: 10.2188/jea.JE20220206
9. Burguin A., Diorio C., Durocher F. Breast Cancer Treatments: Updates and New Challenges. J Pers Med. 2021;11(8):808. DOI: 10.3390/jpm11080808
10. Фролова М.А., Глазкова Е.В., Петровский А.В. и др. Роль неоадъювантного подхода в лечении первично операбельного HER2-позитивного рака молочной железы. Злокачественные опухоли. 2020;10(2):4. DOI: 10.18027/2224-5057-2020-10-2-4Frolova M.A., Glazkova E.V., Petrovsky A.V. et al. The role of the neoadjuvant approach in the treatment of primary operable HER2‑positive breast cancer. Malignant Tumours. 2020;10(2):4 (in Russ.). DOI: 10.18027/2224-5057-2020-10-2-4
11. Rivenbark A.G., O'Connor S.M., Coleman W.B. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183(4):1113–1124. DOI: 10.1016/j.ajpath.2013.08.002
12. Korde L.A., Somerfield M.R., Carey L.A. et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485–1505. DOI: 10.1200/JCO.20.03399
13. Golshan M., Loibl S., Wong S.M. et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from the BrighTNess randomized clinical trial. JAMA Surg. 2020;155(3):e195410. DOI: 10.1001/jamasurg.2019.5410. Erratum in: JAMA Surg. 2021;156(5):503. DOI: 10.1001/jamasurg.2021.0396
14. Морозов Д.А., Колядина И.В., Поддубная И.В. и др. Особенности ответа на неоадъювантную химиотерапию у пациенток с HER2-позитивным раком молочной железы II–III стадии, получающих современные режимы лекарственной терапии с двойной анти-HER2-блокадой (оригинальное исследование). Современная онкология. 2021;23(4):603–609. DOI: 10.26442/18151434.2021.4.201297Morozov D.A., Kolyadina I.V., Poddubnaya I.V. et al. Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III. Journal of Modern Oncology. 2021;23(4):603–609. DOI: 10.26442/18151434.2021.4.201297
15. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. DOI: 10.1126/science.3798106
16. Press M.F., Pike M.C., Chazin V.R. et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53(20):4960–4970. PMID: 8104689
17. Takada M., Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020;9(3):32. DOI: 10.21037/cco-20-123
18. Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–384. DOI: 10.1016/S0140-6736(09)61964-4
19. Villacampa G., Matikas A., Oliveira M. et al. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. Eur J Cancer. 2023;190:112885. DOI: 10.1016/j.ejca.2023.03.042
20. Schneeweiss A., Chia S., Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–2284. DOI: 10.1093/annonc/mdt182
21. Hurvitz S.A., McAndrew N.P., Bardia A. et al. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021;7(1):134. DOI: 10.1038/s41523-021-00342-5
22. Zhang J., Yu Y., Lin Y. et al. Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis. Ther Adv Med Oncol. 2021;13:17588359211006948. DOI: 10.1177/17588359211006948
23. van der Voort A., van Ramshorst M.S., van Werkhoven E.D. et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021;7(7):978–984. DOI: 10.1001/jamaoncol.2021.1371
24. Curigliano G., Burstein H.J., Gnant M. et al.; Consensus Conference Panelists 2023. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34(11):970–986. DOI: 10.1016/j.annonc.2023.08.017
25. Косторов В.А., Семиглазова Т.Ю., Павлыш А.В. Клинические и фармакоэкономические аспекты неоадъювантной терапии HER2-позитивного рака молочной железы. Медицинский совет. 2018;(10):140–145. DOI: 10.21518/2079-701X-2018-10-140-145Kostorov V.A., Semiglazova T.Y., Pavlysh A.V. Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer. Medical Council. 2018;(10):140–145 (in Russ.). DOI: 10.21518/2079-701X-2018-10-140-145
26. Игнатьева В.И., Хачатрян Г.Р. Фармакоэкономический анализ двойной таргетной неоадъювантной терапии у пациенток с HER2 позитивным раком молочной железы. Медицинские технологии. Оценка и выбор. 2016;1(23):45–55.Ignatyeva V.I., Khachatryan G.R. A Pharmacoeconomic Analysis of Dual-Targeted Neoadjuvant Therapy in Female Patients with HER2-Positive Breast Cancer. Medical Technologies. Assessment and Choice. 2016;1(23):45–55 (in Russ.).
27. Carey L.A., Berry D.A., Cirrincione C.T. et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016;34(6):542–549. DOI: 10.1200/JCO.2015.62.1268
28. Llombart-Cussac A., Cortés J., Paré L. et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18(4):545–554. DOI: 10.1016/S1470-2045(17)30021-9
29. Loibl S., Majewski I., Guarneri V. et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2019;30(7):1180. DOI: 10.1093/annonc/mdy536
30. Bianchini G., Kiermaier A., Bianchi G.V. et al. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res. 2017;19(1):16. DOI: 10.1186/s13058-017-0806-9
31. Киселевский М.В., Власенко Р.Я., Заботина Т.Н., Кадагидзе З.Г. Прогностическая значимость опухоль-инфильтрирующих лимфоцитов. Иммунология. 2019;40(1):74–83. DOI: 10.24411/0206-4952-2019-11009Kiselevskiy M.V., Vlasenko R.Ya., Zabotina T.N., Kadagidze Z.G. Prognostic significance of tumor-infiltrating lymphocytes. Immunologiya. 2019;40(1):74–83 (in Russ.). DOI: 10.24411/0206-4952-2019-11009
32. Denkert C., von Minckwitz G., Brase J.C. et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–991. DOI: 10.1200/JCO.2014.58.1967
33. Hong R., Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond). 2022;42(10):913–936. DOI: 10.1002/cac2.12358
34. Fernandez-Martinez A., Pascual T., Singh B. et al. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023;9(4):490–499. DOI: 10.1001/jamaoncol.2022.6288
35. Luque M., Sanz-Álvarez M., Morales-Gallego M. et al. Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. Cancers (Basel). 2022;14(24):6034. DOI: 10.3390/cancers14246034
36. Bidard F.C., Michiels S., Riethdorf S. et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018;110(6):560–567. DOI: 10.1093/jnci/djy018
37. McDonald B.R., Contente-Cuomo T., Sammut S.J. et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019;11(504):eaax7392. DOI: 10.1126/scitranslmed.aax7392
38. Moss J., Zick A., Grinshpun A. et al. Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer. Ann Oncol. 2020;31(3):395–403. DOI: 10.1016/j.annonc.2019.11.014
39. Rothe F., Silva M.J., Venet D. et al. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin Cancer Res. 2019;25:3581–3588. DOI: 10.1158/1078-0432.CCR-18-2521
40. Huang Y., Zhu T., Zhang X. et al. Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study. EClinicalMedicine. 2023;58:101899. DOI: 10.1016/j.eclinm.2023.101899
41. Saha T., Lukong K.E. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance. Front Oncol. 2022;12:856974. DOI: 10.3389/fonc.2022.856974
This work is licensed under a Creative Commons «Attribution» 4.0 License.
